Dupixent Phase III data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years.- Sanofi + Regeneron
The pivotal Phase III clinical trial results announced show Dupixent (dupilumab) combined with standard-of-care topical corticosteroids (TCS) from Sanofi + Regeneron ,in children aged 6-11 years with uncontrolled… read more.